China’s healthcare regulator has defended the efficacy of off-patent medicines it had approved to be distributed through the country’s state hospitals – after complaints saying they were inferior to Western companies’ products – saying an investigation into quality concerns had found them to be unsubstantiated.
The National Healthcare Security Administration (NHSA) said it had performed evaluations to ensure so-called generic drugs were consistent with the quality and efficacy of original research drugs, and strictly supervised them after approval, Reuters reports.
The NHSA launched an investigation last month after local media quoted doctors in Beijing and Shanghai saying that cheaper generic drugs used at public hospitals did not appear to have the same efficacy as those made by Western pharmaceutical companies.
The regulator said it had spoken to relevant experts as well as the heads of seven hospitals and found that perceptions that generic drugs like anaesthetics and laxatives were less effective arose from “subjective feelings”.
China rolled out the bulk-buy programme in 2018 in an attempt to negotiate lower prices from drug manufacturers and has since expanded it to many parts of the country.
The drugs on the list include off-patent blockbusters made by Western pharmaceutical giants as well as generics produced by local players.
While the scheme puts pressure on margins, many drugmakers participate in the tenders to supply public hospitals in large volumes.
Reuters article – China’s health regulator defends quality of local generic drugs (Open access)
See more from MedicalBrief archives:
FDA issues voluntary recall of generic blood pressure drug
Cheaper obesity drugs in Indian and Chinese pipelines
As China’s health system falters, the desperate smuggle drugs or make their own